

Newsletter

Issue 7 • May 2026



Dear Renal Lifecycle participant,


Thank you for participating! In this newsletter, we would like to update you on the progress of the trial. We will also share an update from the Data Safety Monitoring Board (DSMB), look back at how the study started, and introduce another patient representative.

Would you like to share your experiences in this newsletter? Or do you have any questions, comments, or suggestions for the newsletter or the trial? We would be happy to receive them via the following email address: renal.lifecycle.trial@umcg.nl.

Progress update

Thanks to your participation, our study continues to grow. We are proud to share that more than **1750** participants have now joined, across multiple hospitals and countries around the world. Based on the current progress, the study is expected to continue through next year and currently is expected to be completed in the second half of 2027. We will continue to keep you informed about any updates to the timeline. Please find below a graph with top including centers in the past few months.

Top including centers in 2026




Data Safety Monitoring

An independent Data Safety Monitoring Board (DSMB) oversees the Renal Lifecycle Trial to make sure that the study is safe for participants. The board reviews the study data at least every six months and evaluates whether the trial can safely continue. The board includes recently retired medical experts who are not involved in the study. This allows them to provide independent advice. At their last meeting on 24 March 2026, the DSMB found no safety concerns. They also had no concerns about how the study is progressing or about the quality of the data. Thus, the trial can be continued without modification.

New: Share your ideas and feedback via the website

We have added a new chat feature to our [website](https://www.renal-lifecycle.com) where participants and professionals can share their ideas, experiences, and suggestions about the trial. We would love to hear your feedback!



www.renal-lifecycle.com



renal.lifecycle.trial@umcg.nl

How it all started

This study started with a special moment. In January 2021, we received an email from the Piet Poortman Foundation. This foundation was created in honour of Piet Poortman, the owner of a taxi company who drove patients to and from the hospital, including many dialysis patients. Upon his passing, Piet Poortman left funds to support research for these patients, resulting in a generous gift of 4.4 million euros to be spent on research in kidney diseases. The foundation had one requirement. It wanted to support research that has the prospect of **improving care for as many patients as possible over time**. We designed the Renal Lifecycle Trial to meet this requirement.

In February 2021, the trial plan was approved by the Piet Poortman Foundation. From the beginning, the study was designed to be practical. This means:

- As little burden as possible for patients
- As little work as possible for healthcare staff
- Results that can be used directly in daily health care of kidney patients

In June 2022, the study was approved by the Medical Ethics Committee. A few months later, in October 2022, the first patient began with study medication at the UMC Groningen in the Netherlands, marking the official start of the study.



Since then, the study has continued to grow. Many people and hospitals showed interest. As a result, the study has expanded to other countries (Australia, Belgium, Germany, Singapore, and Spain). This expansion is quite unique, as funding is distributed across different organizations.

Introducing another member of the international patient representatives board

After the introduction of several members of the International Patient Representatives Board of the Renal Lifecycle Trial, we would like to introduce another patient representative. If you have questions for the patient representatives, please feel free to reach out to: renal.lifecycle.trial@umcg.nl.

Dean Guinness is patient representative from **Australia**. Although not a participant in the Renal Lifecycle Trial, he brings valuable patient perspective as a kidney transplant recipient. Having followed research on SGLT2 inhibitors for many years, he believes in the growing evidence supporting their benefits for people with kidney disease. Having experience as patient with chronic kidney disease, dialysis, and transplantation in Australia, he is passionate about representing the health interests of all those three groups of kidney patients worldwide. He is also keen to help gather further data for the oftentimes under-represented transplant community, making the Renal Lifecycle Trial especially meaningful.

